Document › Details
Deutsche Biotech Innovativ AG. (11/25/15). "Press Release: Deutsche Biotech Innovativ AG Invests Funds from Capital Increase in Clinical Development of Sepsis Drug Adrecizumab". Hennigsdorf.
|Organisation||Deutsche Biotech Innovativ AG (DBI AG)|
|Group||Deutsche Biotech Innovativ (Group)|
|Organisation 2||AdrenoMed AG|
|Group||Deutsche Biotech Innovativ (Group)|
|Product 2||investment banking|
|Index term||Deutsche Biotech Innovativ–SEVERAL: investment, 201508–201511 capital increase €1.6m 49k new shares €33.5/share out of 596.4k shares on public offer|
|Person||Wegener, Bernd (Deutsche Biotech Innovativ AG before BRAHMS CEO)|
The Deutsche Biotech Innovativ AG ("DBI") was able to generate gross proceeds of over 1.6 million Euros from its current capital increase. In total 48,938 new shares were placed at an issue price of 33.50 Euros. The new shares are expected to be delivered beginning of December 2015.
The proceeds from the capital increase will be invested in particular in the upcoming clinical development of the sepsis drug Adrecizumab which is developed by the project company Adrenomed AG.
"The financing market for biotech companies is difficult in Germany, in particular for young companies. With our first public offering we have therefore not achieved the desired goal, but nevertheless, we will push the further development of our pipeline - also with additional own resources", says Dr. Bernd Wegener, CEO of DBI AG.
The application for the first-in-man clinical study with Adrecizumab is about to be submitted. In this study, the drug will be tested for its safety, tolerability and its effects on the human organism. The study is to be completed in 2016, so that the phase II study can follow directly afterwards in 20 to 30 clinical centers across Europe. The final results of the phase II study are expected by the end of 2018.
About Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapies for serious diseases lacking adequate medical treatment options. Its focus is on drugs for sepsis and cancer. The company's main product is Adrecizumab, a patented drug to reduce mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a phase I study starting end of 2015.
DBI AG aims to further expand its drug pipeline and invest in the research and development of drugs with high unique-selling-point potential.
Both members of DBI AG's Management Board, Dr Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialized in blood biomarkers. It was sold in 2009 for around 330 million euro. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).
For more information, please contact:
Deutsche Biotech Innovativ AG
Ms. Susanne Wallace
Tel.: +49 (0)3302 20 77 811
Kirchhoff Consult AG
Ms. Anja Ben Lekhal
Tel.: +49 (0)40 609 186 55
2015-11-25 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
416159 2015-11-25 show this
Record changed: 2017-04-02
More documents for Deutsche Biotech Innovativ (Group)
-  Deutsche Biotech Innovativ AG. (10/29/15). "Press Release: Capital Increase Deutsche Biotech Innovativ AG – First Public Offer to Private Investors"....
-  Deutsche Biotech Innovativ AG. (8/6/15). "Press Release: Sepsis Drug Adrecizumab Shows High Degree of Efficacy in Preclinical Studies". Hennigsdorf....
-  Deutsche Biotech Innovativ AG. (8/15). "Präsentation: Innnovative Therapies for Unmet Medical Needs. Investorenpräsentation Deutsche Biotech Innovativ AG, August 2015". Hennigsdorf....
-  Deutsche Biotech Innovativ AG. (7/24/15). "Press Release: AGM Approves Bonus Shares and Capital Increase". Hennigsdorf....
-  Deutsche Biotech Innovativ AG. (12/12/14). "Pressemitteilung: Kapitalerhöhung beschlossen und bereits erfolgreich platziert". Hennigsdorf....
-  Deutsche Biotech Innovativ AG. (10/21/14). "Pressemitteilung: Venetus Beteiligungen AG – Umfirmierung in „Deutsche Biotech Innovativ AG“ ist erfolgt". Hennigsdorf....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)